PD-L1 co-expression in both tumor and immune cells was observed in 32% (31/97), 23% (22/97), 10% (10/97), and 11% (11/97) of cases in the 22C3, SP263, SP142, and E1L3N assays, respectively. This evidence concerns the gene CD274 and neoplasm.